Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention

Autor: Yi‐Long Wu, Shun Lu, Ying Cheng, Qing Zhou, Hai‐Yan Tu, Qing‐Hua Zhou, Lv‐Hua Wang, Li Zhang, Jian‐Ying Zhou, Cheng Huang, Ming Chen, Cheng‐Ping Hu, Shao‐Kun Chuai, Xiao‐Nan Wang, Xiao‐Qing Liu, Ji‐Wei Liu, Peng‐Hui Zhou, Wei‐Zhi Chen, Ling‐Hua Yan, Yun‐Peng Liu, An‐Wen Liu, Xu‐Chao Zhang, Hui Li, Rong‐Rong Chen, Dong‐Mei Lin, Cong‐Ying Xie, Zheng‐Fei Zhu, Hui‐Ying Liang, Yong Song, Xiao‐Rong Dong, Ming‐Fang Zhao, Gui‐Bin Qiao, Jiu‐Wei Cui, Zi‐Ming Li, Zhi‐Jie Wang, Xiao‐Yuan Chen, Nong Yang, Gen Lin, Pan‐Wen Tian, Yun Fan, Qi‐Bin Song, Yuan Chen, Jian‐Chun Duan, Jia‐Lei Wang, Bo Zhu, Bu‐Hai Wang, Jun Zhao, Qi‐Tao Yu, Li‐Feng Wang, Hai‐Bo Zhang, Jie Hu, Rui Ma, Tong‐Mei Zhang, Jie Lin, Qian Chu, Sheng‐Xiang Ren, Yu Yao, Lin Wu, Hui‐Juan Wang, Fang Wu, Wen‐Zhao Zhong, Yi Hu, Ke‐Neng Chen, Jian Zhao, Fan Yang, Qun Wang, Dong‐Sheng Yue, Jian‐Ya Zhou, Peng Shen, Jia‐Tao Zhang, Xiao‐Long Yan, Mei‐Juan Huang, Wei‐Neng Feng, Li Li, Chinese Association of Lung Cancer, Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG)

Publikováno v: Medicine Advances, Vol 1, Iss 4, Pp 293-305 (2023)

Abstract The importance of uncommon/rare oncogenic drivers in non‐small cell lung cancer (NSCLC) was underscored during the 20th China Lung Cancer Summit. These drivers, while present in a significant proportion of NSCLC patients, remain a challeng

Externí odkaz: https://doaj.org/article/6cf86ef452334af4a74e37fd66750545

Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non–Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)

Autor: Si-Yang Maggie Liu, Hong-Hong Yan, Xue-Wu Wei, Chang Lu, Xiao-Rong Dong, Yingying Du, Jiu-Wei Cui, Yuan Chen, Rui Ma, Bu-Hai Wang, Zhen Zhou, Shun-Dong Cang, Jin-Ji Yang, Hai-Yan Tu, Xu-Chao Zhang, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu

Publikováno v: Clinical Lung Cancer. 23:e395-e399

With rare genetic variations having been increasingly recognized at a preclinical stage, a variety of early-phase clinical trials have been launched. Due to the low incidence rate of these variations, although the sample size of trials are small, it

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac4c937cc5a9f821e6e6d87e2faf61bc
https://doi.org/10.1016/j.cllc.2022.05.009

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

Autor: M. Saggese, Minhao Fan, Chunling Liu, Andrew Walding, Helong Zhang, Jia Wang, Wei Li, Yong He, X. Huang, Bu-Hai Wang, Qing Zhou, Ying Cheng, Suresh S. Ramalingam

Publikováno v: Targeted Oncology

Background In the global FLAURA study, first-line osimertinib, a third-generation irreversible tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), significantly improved progression-free survival (PFS) and overall survival (OS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::698b996c09128adc0587269c977eefbe
http://europepmc.org/articles/PMC7935816

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Autor: Yedan Chen, Shengxiang Ren, Weimin Mao, Yang Shao, Xue-Ning Yang, Xu-Chao Zhang, Lin Wu, Hua Bao, Ping Yu, Bu-Hai Wang, Si-Yang Liu, Jin-Ji Yang, Qing Zhou, Zhidong Liu, Qun Wang, Yi-Long Wu, Ke-Neng Chen, Song Dong, Haitao Ma, Rong Yin, Cheng Huang, Fan Yang, Lunxu Liu, Yongyu Liu, Xiaofei Li, Song-Tao Xu, Chun Chen, Wen-Zhao Zhong, Xiaoling Tong, Jian Li, Shidong Xu, Xue Wu, Jian Su, Shun Xu, Yucheng Wei, Ying Cheng, Hong-Hong Yan

Publikováno v: Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)

The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival of resected EGFR-mutant stage II–IIIA non-small cell lung cancer (NSCLC). However, not all patients experienced favorable clini

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de0c43565a4b8e24467e87fb47d6de05
https://doi.org/10.1038/s41467-021-26806-7

Abstract 5091: The early change of serum interleukin 14α levels predicts the response to anti-PD-1 therapy in cancer

Autor: Bu Hai Wang, Cai Yue Chen, Xian Zhang, Yu Xiang Huang, Yi Chun Zeng, Lei Li, Mao Qi Wang, Jing Liang Guo, Qiu Xian Li, Long Shen, Juan J. Gu, Yi Chen Liang

Publikováno v: Cancer Research. 82:5091-5091

Background: Targeting programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) has been shown improved clinical efficacy in a wide range of tumor types. We evaluated serum interleukin 14α (IL14α) as a biomarker to predict the respon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a5a30ed86d8a51a2f99b00efb372ba1c
https://doi.org/10.1158/1538-7445.am2022-5091